1. Introduction
===============

Eisenmenger syndrome (ES) is the most advanced form of pulmonary arterial hypertension (PAH) that is defined as congenital heart disease (CHD) associated with an initial great systemic-to-pulmonary shunt, inducing an elevated vascular resistance with a reverse direction.^\[[@R1]\]^ As reported in western countries, the prevalence of PAH-CHD is 1.6 to 12.5 cases per million adults, commonly resulted from atrial septal defects (ASD), ventricular septal defects (VSD), patent ductus arteriosus (PDA), and more in complex lesions.^\[[@R2]\]^ And 25% to 50% of this population affected by ES, with a progressive deterioration over time.^\[[@R3]\]^ And patients with Down syndrome (DS) are considered as an important subgroup in ES population who suffered from a risk of a worse exercise capacity and cardiopulmonary functions.^\[[@R4]\]^ ES is characterized as an elevated vascular resistance persistently, leading to progressive cyanosis, an impaired exercise capacity proportional to the degree of hypoxemia, and a reduced life expectancy.^\[[@R5]\]^ When untreated, adult populations with ES might exhibit a better survival and prognosis than idiopathic PAH, even presenting an 50% to 80% survival rate at 10 to 20 years. However, a numerous of life-threatening complications in ES conditions, such as cerebrovascular accidents, hemoptysis, and syncope, which indicated a poor quality of life.^\[[@R6]\]^

Historically, the options for patients with ES are limited with a principle to avoid any factors affecting the physiology. The conditional drugs, including digoxin, diuretics, antiarrhythmic agents, and anticoagulants, were aimed to improve clinical symptoms temporarily, with a disappointing prognosis. And when severely incapacitated, lung transplantation or heart--lung transplantation was to be selected.^\[[@R7]\]^ Hence, the therapeutic strategy of these patients carries a greater importance. The 3 major classes of agents targeting the correction pathways of abnormalities in endothelial dysfunction were involved in the pathogenesis of PAH, which have been approved for a significant improvement as followed: endothelin receptor antagonists (ERAs); phosphodiesterase-5 inhibitors (PDE5i); and prostacyclin derivatives (prostanoids).^\[[@R8]\]^ Nevertheless, the therapeutic strategy of patients with ES is mainly based on clinical experience rather than being evidence based. Therefore, we conducted this systematic review and meta-analysis to address the efficacy and safety of pulmonary arterial hypertension-specific drug therapy (PAH-SDT) for patients with ES.

2. Methods
==========

This systematic review and meta-analysis is based on the recommendations on the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement.^\[[@R9]\]^ Two independent reviewers (QL and HYK) have conducted the literature search, eligibility assessment, data extraction, and meta-analysis. All the enrolled citations were limited in English. As this study was a review of studies published, the ethical approval was waved.

2.1. Literature search and selection
------------------------------------

Databases including PubMed, EMBASE, the Cochrane Library databases of Systematic Reviews were searched up to January 2019. We have applied the search strategy "pulmonary arterial hypertension" paired with "Eisenmenger syndrome," and in combination with "endothelin receptor antagonists," "phosphodiesterase-5 inhibitors," or "prostanoids." In addition, manual retrieval of the cited references and related reviews was conducted for any potentially eligible literatures. The studies having been screened for twice, any discrepancies were resolved by a discussion with the corresponding author (QJY) for a consensus. We should contact the authors to get the original data through e-mail when it is necessary.

Each citation was pooled when meeting the criteria as follows: study design: a cohort report treated with PAH-SDT from a randomized controlled trial (RCT), case-control study, and observational study (prospective or retrospective). Participants: ES population with or without Trisomy 21 (DS), and none had received previous PST or a switched pharmacotherapy during treatment. Interventions: PAH-SDT, such as ERAs (bosentan, ambrisentan, macitentan), PDE5i (sildenafil, tadalafil), or prostanoids (epoprostenol, treprostinil, iloprost, beraprost). Outcomes: the enrolled citations should display the assessment of at least one of the following outcome: primary outcomes (rate of deterioration, 6MWD, FC) or any secondary outcomes, such as oxygen saturation (SpO~2~), Borg dyspnea index (BDI), heart rate (HR), mean pulmonary arterial pressure (mPAP), pulmonary vascular resistance (PVR), meanwhile AEs were recorded.

The studies were excluded as: the duplicated studies, case reports (\<5 cases), review, meta-analysis, animal experiments; the study with previous medications or a combined therapy of PAH-specific agents; the population of researches recruited other types of PAH; lacking important outcomes. Any discrepancies about the inclusion and exclusion of each study were determined by a discussion with Q-JY.

2.2. Study quality evaluation and data extraction
-------------------------------------------------

After a retrieval, the quality of the literatures has been assessed by 2 independent reviews (QL and HYK). We adopted the Newcastle-Ottawa Scale for evaluating the methodological quality (<http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp>). And quality assessment including 3 main domains, involving selection domain: representativeness of exposed cohort; selection of non-exposed cohort; ascertainment of exposure to implants; demonstration that outcome, comparability domain, and outcome domain: assessment, enough period of follow-up, adequacy of follow-up of cohorts. A study could be awarded a maximum of 1 star for each numbered item within the Selection and Outcome domain. And for comparability, a maximum of 2 stars can be given. The full mark of total score is defined as 9, and a score no \<7 indicates a high quality.^\[[@R10]\]^ The relevant data were documented by the 2 review authors from each study using a standard data form, of which the items included study characteristics (first author, publication year, study design, subjects), the proportion of ES etiologies, including ASD, VSD, PDA, atrioventricular canal (AVC), and other complex CHD (TOF, single ventricular, TGA) or compound CHD, medical intervention, primary endpoint, and rate of loss. A short-term period has been defined as no more than 1 year (12 months) in this systematic review.

2.3. Statistical analysis
-------------------------

The selected studies were researched and analyzed by the statistical software Stata 15.1 (StataCorp, TX). To evaluate the safety of medications, the occurrence of clinical deterioration and rate of AEs scenario have been displayed as a percentage, and WMD with 95% CI for continuous data. Heterogeneity was tested using Cochrane *Q* test, quantifying with the *I*^2^ statistic. When *P* \< .05 or *I*^2^ \> 50%, it indicated a significant heterogeneity between studies, and then a sensitivity analysis or subgroup analysis was used to explore the sources. After unavailability of homogenization, a random effect model of analysis was employed. Otherwise, a fixed effect model of analysis was applied. Begg test was carried out to investigate publication bias of enrolled studies. In this research, it is stated that *P* \< .05 as statistically significant.

3. Results
==========

3.1. Eligible studies and characteristics
-----------------------------------------

The selection process has been portrayed in Fig. [1](#F1){ref-type="fig"}. A sum up of 170 citations were identified from the primary database search, finally 15 of which meet the inclusion criteria those were pooled in this qualitative systematic review, including 4 RCTs, 6 prospective cohort studies, and 5 retrospective studies.^\[[@R11]--[@R25]\]^ It enrolled 456 patients with ES treated with PAH-SDT, which was recorded caused by different types of CHD, accordingly indicating 16.4% with ASD, 45.9% with VSD, 7.7% with PDA, 2.3% with AVC, 23.0% ES individuals were suffered from a complex CHD or compound CHD, and about 5% with unclear types. The specific-therapy of ES in this systematic review and meta-analysis contained 9 studies with ERAs, 3 studies with PDE-5i, and 3 studies with prostanoids, and these patients had no treatment regimen changes. Additionally, the incidence of dual ES and DS were revealed in patients accounting for 11.8%. The characteristics of enrolled studies were shown in Table [1](#T1){ref-type="table"}.

![Selection flowchart of literature screening for this meta-analysis.](medi-98-e15632-g001){#F1}
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Basic characteristics of pooled studies.
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3.2. Comparative outcomes
-------------------------

### 3.2.1. Efficacy in different terms

After a pharmacotherapy of PAH-SDT, the change of exercise capacity and cardiopulmonary hemodynamics from baseline were evaluated in this research. Within the first year, a meta-analysis of 6MWD was firstly conducted, and heterogeneity test revealed a significant one with a chi-squared = 83.1% (*P*~h~ \< .001) in 12 studies covering 6 ERAs, 3 PDE5i, and 3 prostanoids. A sensitivity analysis was employed indicating a deviation from the research conducted by Bharani et al.^\[[@R21]\]^ After the deviated study excluded, a randomized-effect model has been used (*I*^2^ = 60.5%), demonstrating that PAH-SDT could significantly improve 6MWD by 53.86 m (*I*^2^ = 60.5%; 95% CI \[36.59, 71.13\], *P* \< .001), which was shown in Fig. [2](#F2){ref-type="fig"}. Additionally, FC was also ameliorated in an early targeted therapy with a statistical significance at the early period (*I*^2^ = 85.5%; WMD = --0.71, 95% CI \[--0.98, --0.44\], *P* \< .001), and a subgroup analysis further proved it. As to the exercise parameters, BDI was demonstrated an obvious decrease with statistical significance in 3 studies^\[[@R14],[@R20],[@R21]\]^ (*I*^2^ = 0.0%, WMD = --1.28, 95% CI \[--1.86, --0.70\], *P* \< .001). Meanwhile, PAH-SDT was identified significantly elevate rest SpO~2~ (*I*^2^ = 67.6%, WMD = 2.09%, 95% CI \[0.66%, 3.51%\], *P* = .004) as well as a decreased HR (*I*^2^ = 0.0%, WMD = --1.89, 95% CI \[--3.67, --0.12\], *P* = .036), but an unsatisfactory improvement in SpO~2~ at the end of 6MWD (*P* = .747). For hemodynamics in patients with ES, PAH-SDT monotherapy could greatly lower mPAP (*I*^2^ = 0.0%; WMD: --5.70 mmHg, 95% CI \[--8.19, --3.22\], *P* \< .001) and PVR (*I*^2^ = 67.3%; WMD: --4.20 wood U, 95% CI \[--7.32, --1.09\], *P* = .008).

![Meta-analysis of 6WMD in patients with ES treated with PAH-SDT in a short term. ES = Eisenmenger syndrome, PAH-SDT = PAH-specific drug therapy, WMD = weighted mean differences.](medi-98-e15632-g003){#F2}

In this systematic review, there existed rare evidence about the efficacy and safety of PDE5i and prostanoids in a prolonged medication. A meta-analysis indicted ERAs could contribute to an enhanced 6MWD by 75.24 m (*I*^2^ = 48.2%; WMD: 79.24 m, \[47.81, 110.7\], *P* \< .001). For hemodynamics, only one study indicated a decrease of mPAP from 59 ± 16 to 47 ± 17 mmHg with bosentan about 19 months.^\[[@R11]\]^

### 3.2.2. ERAs

Currently, a total of 9 studies researched the efficacy of ERAs,^\[[@R11]--[@R19]\]^ including bosentan (n = 7),^\[[@R11]--[@R17]\]^ macitentan (n = 1),^\[[@R18]\]^ and ambrisentan (n = 1).^\[[@R19]\]^ In hemodynamics, monotherapy of ERAs was associated with a significant increase, especially in mPAP (*I*^2^ = 0.0%; WMD: --6.38 mmHg, 95% CI \[--9.39, --3.38\], *P* \< .001). Clinically, meta-analysis and subgroup analysis were conducted to evaluate the clinical efficacy of ERAs monotherapy on ES, respectively, in 6MWD (Fig. [3](#F3){ref-type="fig"}), FC, and exercise parameters.

![Meta-analysis of 6MWD in patients with ES treated with ERAs. 6MWD = 6-minute walk distance, ERAs = endothelin receptor antagonists, ES = Eisenmenger syndrome.](medi-98-e15632-g004){#F3}

Bosentan, a dual ERA, could greatly increase distance by 66.16 m (*I*^2^ = 0.0%; WMD: 66.16 m, 95% CI \[59.7, 72.6\], *P* \< .001) in a short term and by 88.68 m (*I*^2^ = 47.5%, 95% CI \[54.05, 123.3\], *P* \< .001) in a prolonged medication. It also demonstrated that bosentan acted as an important role in decreasing the grade of FC by 0.67 (*I*^2^ = 0.0%; WMD: --0.67, 95% CI \[--0.21, 0.05\], *P* \< .001), and a lasting effect after 12 months (*I*^2^ = 0.0%; WMD = --0.65, 95% CI \[--1.10, --0.19\], *P* = .006). Within the first year, bosentan was associated with unsatisfactory change in exercise parameters (HR: *I*^2^ = 68.4%; WMD = 0.55, 95% CI \[--11.68, 12.79\], *P* = .93; SpO~2~: *I*^2^ = 55.3%; WMD = 2.05%, 95% CI \[--0.91, 5.02\], *P* = .18), but a significant improvement of SpO~2~ by 4.06% (*P* = .015). Macitentan was reported in a 16-week RCT, which has been indicated an unsatisfactory increase from baseline (WMD: 18.4 m, *P* = .119), associated with a minor functional benefit in FC (WMD: --0.08, *P* = .241). Ambrisentan has been noted a nonsignificant change of 6MWD in both a short-term (*P* = .280) and long-term therapy (*P* = .385).

Two trials determined the symptomatic benefits and cardiac function of dual ERAs in Eisenmenger and Down syndrome. Crepaz et al^\[[@R12]\]^ assessed the effect of bosentan monotherapy for an assessment and the mean 6MWD increased from 199.6 ± 69.1 m at baseline versus 303.7 ± 99.9 m (*P* = .016), in addition to a significant change of mean SpO~2~ at the end of 6MWD, while without an obvious decrease of BDI (from 3.6 ± 1.4 to 2.4 ± 1.1), approving a possible improvement of clinical exercise capacity. In the Serino et al study,^\[[@R13]\]^ it more identified that trisomy 21 influenced the response little to a dual ERA bosentan therapy in ES patients.

### 3.2.3. PDE5i

The therapeutic effects of PDE5i monotherapy were described in 3 studies.^\[[@R20]--[@R22]\]^ A meta-analysis in 6MWD was not applied for an unacceptable heterogeneity (*I*^2^ \> 85%). There proved a mean increased distance was 80.76 m following an administration in a short-term therapy. In addition, an obvious improvement of FC (*I*^2^ = 0.0%; WMD = --0.31, 95% CI \[--0.42, --0.20\], *P* \< .001) and BDI (*I*^2^ = 67.8%; WMD = --1.44, 95% CI \[--2.52, --0.36\], *P* = .009) were analyzed, proving a significant improvement in exercise functions. Zhang et al^\[[@R20]\]^ and Mukhopadhyay et al^\[[@R22]\]^ reported data on hemodynamics, which indicated a nonsignificant decrease in mPAP (*I*^2^ = 0.0%; WMD = --4.04 mmHg, 95% CI \[--8.58, 0.51\], *P* = .082), but a great change in PVR (*I*^2^ = 0.0%; WMD = --6.10 wood U, 95% CI \[--9.14, --3.95, *P* \< .001).

### 3.2.4. Prostanoids

In 3 trials concentrated on the prostanoids for ES patients.^\[[@R23]--[@R25]\]^ Indicators of exercise capacity were evaluated by a meta-analysis and subgroup analysis, certifying a significant improvement in 6MWD (Ilo: *I*^2^ = 0.0%; WMD: 85.14 m, 95% CI \[46.13, 124.15\], *P* \< .001; Epo: WMD: 203.6 m, 95% CI \[47.27, 359.93\], *P* = .011), and a functional benefit in FC was shown by 1.41 in iloprost (*I*^2^ = 0.0%; 95% CI \[--1.39, --0.89\], *P* \< .001), and 1.62 in epoprostenol (95% CI \[--2.24, --1.00\], *P* \< .001). For vascular changes, Cha et al^\[[@R24]\]^ found an inhaled iloprost could lead to an improvement in mPAP about 17.9, and in PVR about 10.9%. Meanwhile, epoprostenol has been recorded to decrease PVR of ES about 34.8%, from 41.4 ± 18.2 wood U to 27.0 ± 13.2 wood U.

3.3. Safety
-----------

Most PAH-specific drugs were proved generally well tolerated and no serious adverse events occurred eventually. The rate of clinical deterioration was calculated as 7.9% overall, indicating 8.7% in ERAs therapy and 8.3% in PDE-5i therapy. In ERAs monotherapy, the mortality of ES was about 3.9%, while rare death events in PDE5i and prostanoids. Totally, 44.1% ES patients were found AEs scenarios overall specific therapy. Having individuals received ERAs, AEs were recorded commonly as liver dysfunction (20.7%), peripheral edema (17.8%), and headache (14.8%), in addition to serious AEs in 4.3%. While the PDE-5i could contribute to a headache in 36.6% patients, flushing in 29.3%, and nasal congestion in 7.3%. No adverse drug reactions were noted in a short-term inhaled iloprost management.

3.4. Quality assessment
-----------------------

The quality of each study is evaluated according to newcastle-ottawa scale shown in Table [2](#T2){ref-type="table"}. It indicated the pooled studies were of high quality except for 1 study.^\[[@R13]\]^

###### 

Assessment the quality of cohort studies in ES patients^∗^.

![](medi-98-e15632-g005)

3.5. Publication bias
---------------------

There existed no significant proof of publication bias by the inspection of PAH-SDT acting on 6MWD at an early endpoint reported (*P* = .631). And the funnel plot of Begg test was shown in Fig. [4](#F4){ref-type="fig"}.

![Begg funnel plot of 6WMD at an early stage of PAH-SDT acting on ES. ES = Eisenmenger syndrome, PAH-SDT = PAH-specific drug therapy, WMD = weighted mean differences](medi-98-e15632-g006){#F4}

4. Discussion
=============

When associated with CHD, PAH could be a devastating condition suffered from a persistent exposure of the pulmonary vasculature to this increased blood flow causes some obstructive lesions in pulmonary arteriopathy.^\[[@R26]\]^ And this irreversible remodeling could lead to an extreme risk factor of operation, even a poor postoperative outcome after a repair of CHD. Once the pulmonary vascular resistance exceeded systemic circulation resistance, will result in the shunt reversal, and ES condition occurred.^\[[@R27]\]^ In this scenario, patients could experience the apparent functional impairment in the advanced stages primarily, with the signs and symptoms, such as central cyanosis, dyspnea, fatigue, and syncope, etc. Even, right heart failure is a potential complication.^\[[@R28]\]^ The limited exercise tolerance and exertional dyspnea could remain persistent for years, which identify a risk for hospitalization, severe cardiovascular events, or death point. Inai^\[[@R29]\]^ concluded that pulmonary vasodilators are probably available to interfere with the ongoing disease process to improve functional capacity and delay the decision for transplantation with no conclusive evidence. Although retrospective studies suggested ES patients with PAH-SDT benefitted from a longer lifespan, improved hemodynamics lasting period for operation, no recommendations for patients with ES have existed.^\[[@R30],[@R31]\]^

The present review enrolled researches reporting different novel pulmonary vasodilators against 3 pathophysiological pathways in ES, involving ERAs (60.0%), PDE-5i (20.0%), and prostanoids (20.0%). However, sitaxsentan, a selective ERA, has been removed from the market for a deadly dysfunction of liver in 2010. We have found that almost 45.9% patients with Eisenmenger syndrome in this study were caused by VSD, and 16.4% with ASD, 7.7% with PDA, 2.3% with AVC. And 23% ES individuals were ascribed to a complex or compound CHD, which were basically accordance to the findings recorded by Kidd et al^\[[@R32]\]^ and Vongpatanasin et al^\[[@R33]\]^ before. Almost all specific drugs were well tolerated with a low risk of death and clinical deterioration in a short-term treatment. Almost all drawbacks and AEs of PDE5i and prostanoids were mild to moderate in intensity. While, 13 serious AE scenarios were observed in ERAs therapy, of which a greater proportion with a dysfunction of hepatic, in addition to vasovagal syncope, angina pectoris, and sinus tachycardia.

In a short-term treatment of PAH-SDT monotherapy to patients with ES (≤12 months), 6MWD, as an important surveillance of exercise tolerance, was significantly improved (WMD: 53.86 m, 95% CI \[36.59, 71.13\], *P* \< .001), in addition that it could contribute to some clinical functional benefits lowering FC grade (*P* \< .001) and BDIs (*P* \< .001), clinically with a higher rest SpO~2~ (*P* = .004) and a lower HR (*P* = .036). Meanwhile improved cardiopulmonary parameters, especially mPAP and PVR, demonstrated that the specific vasodilators could greatly relieve the progress in vascular remodeling, with a WMD of --5.70 mmHg for mPAP (*P* \< .001) and --4.20 wood U for PVR (*P* = .008). However, a short-term medication probably could not mediate SpO~2~ at exercise (*P* = .747), which hinted a potential danger of cyanosis and severe cardiovascular events as exercise moments. However, there existed limited evidence about the efficacy and safety of PAH-SDT in a prolonged medication, which indicated ERAs could improve exercise tolerance.

Our review analyzed the subgroup of PAH-specific drugs in different pathways. Firstly, ERAs could contribute to an improve exercise capacity and vascular remodeling of patients with ES within the first year. Subgroup analysis indicated bosentan, a dual ERA, could significantly improve 6MWD (WMD: 66.16 m, 95% CI \[59.7, 72.6\], *P* \< .001) and FC (WMD: --0.67, 95% CI \[--0.21, 0.05\], *P* \< .001) in a short term, moreover, enhanced functional benefits of which were proved in a prolonged treatment. It was associated with an increase of 6MWD by 88.68 m (*I*^2^ = 47.5%, 95% CI \[54.05, 123.3\], *P* \< .001) and a decrease of FC by 0.65 (95% CI \[--1.10, --0.19\], *P* = .006). Although unsatisfactory outcomes were observed in HR and SpO~2~ with bosentan in a short term, a significant improvement of SpO~2~ was associated with a lasting therapy, identifying a maintained treatment of bosentan for ES might be effective. Hence, bosentan in ES patients is confirmed as a safe, well tolerated and effective therapy with or without DS, which is probably accord with the outcomes approved by Hascoet in 2017.^\[[@R34]\]^ Nevertheless, macitentan and ambrisentan could contribute to a non-significant amelioration in exercise capacity and cardiopulmonary hemodynamics compared with those at baseline. For safety, ERAs could result in some AE conditions, mostly as mild to moderate, such as an increase of hepatic transaminase levels, headache, and peripheral edema. Still, there existed 4.3% individuals treated with ERAs suffered from serious AEs, showing a potential risk of deadly liver dysfunction, arrhythmia, heart failure etc.,^\[[@R15],[@R17],[@R18]\]^ and 3.9% suffered from death.

In the first year, PDE5i could improve 6WMD (WMD: 80.76 m, 95% CI: \[19.46, 142.05\], *P* = .01), FC (WMD: --0.31, 95% CI \[--0.42, --0.20\], *P* \< .001), and PVR (WMD: --6.10 wood U, 95% CI \[--9.14, --3.95, *P* \< .001). And some AEs, like headache, edema, flushing, and nasal congestion, were commonly recorded with a PDE-5i management (sildenafil and tadalafil). No deaths and severe adverse events occurred. Data on prostanoids in patients with ES are limited to small sample size studies and case reports previously, and the long-term effects of prostanoids remain unknown. It is previously proved continuous prostacyclin analogs contribute to some maintained effects in a long-term therapy on PAH-CHD, including Eisenmenger syndrome.^\[[@R35]\]^ Limsuwan et al^\[[@R36]\]^ has presented a report on children with serious PH-CHD with beraprost treatment for 6 months, showing a reduced level of the pulmonary-to-systemic vascular resistance ratio, without a significant change of pulmonary vascular remodeling. We meta-analyzed 6MWD and FC as the measure of exercise tolerance, showing that inhaled iloprost for 6 to 12 months was associated with an improvement in 6MWD by 85.14 m (*P* \< .001), and in FC by 1.41 (*P* \< .001). For vascular changes, Cha et al^\[[@R24]\]^ found an inhaled iloprost could lead to an improvement in mPAP about 17.9% and PVR about 10.9%. Also, epoprostenol has been demonstrated to greatly improve exercise capacity and cardiopulmonary hemodynamics for ES with limited functional capacity (FC III or IV).

Some limitations still existed in this review: some investigators did not perform an invasive evaluation such as right cardiac catheterization during follow-up visits; most of the pooled trials had a relatively small sample size, and we only concentrated on the cohorts of ES patients interfered with active drugs which neglected a comparative effect from placebo or control group; the enrolled studies were limited to describe the safety and efficacy of medications, and no combined outcomes were concentrated on. The duration of studies ranged from 1 month to 24 months, lacking lasting clinical worsening, deterioration, AEs, exercise capacity, quality of life and reversal of pulmonary changes at 5 years or 10 years. There lacked evidence concentrating on the efficacy and safety of PDE5i and prostanoids for ES in a long-term.

5. Conclusions
==============

In a conclusion, PAH-SDT can induce an early relief in clinical status and cardiopulmonary hemodynamics of ES patients. However, there probably still existed a limited exercise ability with PAH-SDT in a short term, hinting an acute cardiovascular event at exercise. Among the specific agents in this review, bosentan, an active dual ERA, is a commonest application as safe and effective in ES with or without DS. Still, a minority of death or serious AEs could occur ascribed to it during a short-term. It also indicated that PDE-5i and inhaled iloprost could temporarily ameliorate exercise tolerance, functional grade, in addition to favorable short-term outcomes in hemodynamic parameters, with mild to moderate AEs. Even lung transplantation with repair of the cardiac defect or combined heart--lung transplantation are options for Eisenmenger syndrome patients with a poor prognosis, an early PAH-SDT could delay the process of PAH, expanding the operative indications for ES, and a maintained efficacy is obtained with a prolonged therapy at least over 12 months. Furthermore, a combined therapy should be considered for a better safety and efficiency, without severe active drug responses.
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